1
|
Murthy VL, Mosley JD, Perry AS, Jacobs DR, Tanriverdi K, Zhao S, Sawicki KT, Carnethon M, Wilkins JT, Nayor M, Das S, Abel ED, Freedman JE, Clish CB, Shah RV. Metabolic liability for weight gain in early adulthood. Cell Rep Med 2024; 5:101548. [PMID: 38703763 PMCID: PMC11148768 DOI: 10.1016/j.xcrm.2024.101548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 03/27/2023] [Accepted: 04/10/2024] [Indexed: 05/06/2024]
Abstract
While weight gain is associated with a host of chronic illnesses, efforts in obesity have relied on single "snapshots" of body mass index (BMI) to guide genetic and molecular discovery. Here, we study >2,000 young adults with metabolomics and proteomics to identify a metabolic liability to weight gain in early adulthood. Using longitudinal regression and penalized regression, we identify a metabolic signature for weight liability, associated with a 2.6% (2.0%-3.2%, p = 7.5 × 10-19) gain in BMI over ≈20 years per SD higher score, after comprehensive adjustment. Identified molecules specified mechanisms of weight gain, including hunger and appetite regulation, energy expenditure, gut microbial metabolism, and host interaction with external exposure. Integration of longitudinal and concurrent measures in regression with Mendelian randomization highlights the complexity of metabolic regulation of weight gain, suggesting caution in interpretation of epidemiologic or genetic effect estimates traditionally used in metabolic research.
Collapse
Affiliation(s)
- Venkatesh L Murthy
- Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
| | - Jonathan D Mosley
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Andrew S Perry
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - David R Jacobs
- Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA
| | - Kahraman Tanriverdi
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Shilin Zhao
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | | | | | | | - Matthew Nayor
- Section of Cardiovascular Medicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
| | - Saumya Das
- Cardiology Division, Massachusetts General Hospital, Boston, MA, USA
| | - E Dale Abel
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA
| | - Jane E Freedman
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Clary B Clish
- Broad Institute of Harvard and MIT, Cambridge, MA, USA
| | - Ravi V Shah
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
| |
Collapse
|
2
|
Cao Q, Li M, Qin G, Yan L, He J, Xu M, Xu Y, Wang T, Chen Y, Wang S, Lin H, Zhao Z, Gao Z, Zeng T, Hu R, Yu X, Chen G, Su Q, Mu Y, Chen L, Tang X, Wan Q, Wang G, Shen F, Luo Z, Qin Y, Chen L, Huo Y, Li Q, Ye Z, Zhang Y, Liu C, Wang Y, Wu S, Yang T, Deng H, Zhao J, Shi L, Ning G, Wang W, Lu J, Bi Y. Early adulthood weight change, midlife "Life's essential 8" health status and risk of cardiometabolic diseases: a chinese nationwide cohort study. Nutr Metab (Lond) 2023; 20:48. [PMID: 37915057 PMCID: PMC10621175 DOI: 10.1186/s12986-023-00765-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Accepted: 10/04/2023] [Indexed: 11/03/2023] Open
Abstract
BACKGROUND The association between weight change during early adulthood and cardiometabolic diseases remains uncertain in Chinese population. Whether the association varies with comprehensive cardiovascular health (CVH) in midlife assessed by "Life's Essential 8" has not been characterized. We aim to examine the associations of early adulthood weight change and midlife "Life's Essential 8" CVH status with cardiometabolic outcomes in a Chinese cohort. METHODS The study participants were from the China Cardiometabolic Disease and Cancer Cohort (4 C) Study. This analysis included 72,610 middle-aged and older participants followed for a median of 3.6 years. At baseline, the participants recalled body weight at age 20 and 40 years, and we calculated change in weight and BMI between 20 and 40 years of age. Health behaviors information in "Life's Essential 8" was collected by questionnaire, and health factors were measured in the study center. During follow-up, we ascertained incident cardiovascular events based on medical records, and diagnosed incident diabetes according to the American Diabetes Association 2010 criteria. RESULTS 72,610 study participants were included with a mean age of 56.0 ± 8.8 years and 29% of them were males. Weight gain of more than 10 kg between 20 and 40 years of age was associated with 22% increased risk of incident cardiovascular events (HR: 1.22; 95%CI: 1.04-1.43) and 38% increased risk of diabetes (HR: 1.38; 95%CI: 1.25-1.53) compared to stable weight. Besides, the association of weight gain more than 10 kg in early adulthood with cardiometabolic risk was even stronger in those with low CVH score in midlife (HR: 2.44; 95%CI: 2.01-2.97 for incident cardiovascular events; HR: 2.20; 95%CI: 1.90-2.55 for incident diabetes) or with few ideal cardiovascular health metrics in midlife. CONCLUSIONS Our study indicated that weight gain in early adulthood was associated with significantly increased risk of cardiometabolic diseases. And the association could be stronger in those with poor CVH profiles in midlife. These findings confirmed the significance of weight management during early adulthood and suggested that individuals who experienced substantial weight gain in early life should be encouraged to maintain good CVH status in Chinese population.
Collapse
Grants
- 21QA1408100 Shanghai Rising-Star Program
- 2022ZD0162102 National Key Research and Development Program of China
- 81970728, 82022011, 82088102, 91857205, 81930021 National Natural Science Foundation of China
- 81970728, 82022011, 82088102, 91857205, 81930021 National Natural Science Foundation of China
- 81970728, 82022011, 82088102, 91857205, 81930021 National Natural Science Foundation of China
- 81970728, 82022011, 82088102, 91857205, 81930021 National Natural Science Foundation of China
- 22Y31900300 Shanghai Municipal People's Government
- Shanghai Municipal People’s Government
Collapse
Affiliation(s)
- Qiuyu Cao
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Mian Li
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Guijun Qin
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Li Yan
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
| | - Jiang He
- Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, USA
| | - Min Xu
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yu Xu
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Tiange Wang
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yuhong Chen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Shuangyuan Wang
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Hong Lin
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Zhiyun Zhao
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Zhengnan Gao
- Dalian Municipal Central Hospital, Dalian, China
| | - Tianshu Zeng
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Ruying Hu
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| | - Xuefeng Yu
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Gang Chen
- Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China
| | - Qing Su
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yiming Mu
- Chinese people's Liberation Army General Hospital, Beijing, China
| | - Lulu Chen
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Xulei Tang
- The First Hospital of Lanzhou University, Lanzhou, China
| | - Qin Wan
- The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Guixia Wang
- The First Hospital of Jilin University, Changchun, China
| | - Feixia Shen
- The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
| | - Zuojie Luo
- The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Yingfen Qin
- The First Affiliated Hospital of Guangxi Medical University, Nanning, China
| | - Li Chen
- Qilu Hospital of Shandong University, Jinan, China
| | - Yanan Huo
- Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang, China
| | - Qiang Li
- The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Zhen Ye
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| | - Yinfei Zhang
- Central Hospital of Shanghai Jiading District, Shanghai, China
| | - Chao Liu
- Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China
| | - Youmin Wang
- The First Affiliated Hospital of Anhui Medical University, Hefei, China
| | - Shengli Wu
- Karamay Municipal People's Hospital, Xinjiang, China
| | - Tao Yang
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Huacong Deng
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
| | - Jiajun Zhao
- Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| | - Lixin Shi
- Guiqian International General Hospital, Guiyang, China
| | - Guang Ning
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Weiqing Wang
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Jieli Lu
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| | - Yufang Bi
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui-Jin 2nd Road, Shanghai, 200025, China.
- Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
| |
Collapse
|
3
|
Faquih TO, Aziz NA, Gardiner SL, Li-Gao R, de Mutsert R, Milaneschi Y, Trompet S, Jukema JW, Rosendaal FR, van Hylckama Vlieg A, van Dijk KW, Mook-Kanamori DO. Normal range CAG repeat size variations in the HTT gene are associated with an adverse lipoprotein profile partially mediated by body mass index. Hum Mol Genet 2023; 32:1741-1752. [PMID: 36715614 PMCID: PMC10448954 DOI: 10.1093/hmg/ddad020] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Revised: 11/18/2022] [Accepted: 11/26/2023] [Indexed: 01/31/2023] Open
Abstract
Tandem cytosine-adenine-guanine (CAG) repeat sizes of 36 or more in the huntingtin gene (HTT) cause Huntington's disease (HD). Apart from neuropsychiatric complications, the disease is also accompanied by metabolic dysregulation and weight loss, which contribute to a progressive functional decline. Recent studies also reported an association between repeats below the pathogenic threshold (<36) for HD and body mass index (BMI), suggesting that HTT repeat sizes in the non-pathogenic range are associated with metabolic dysregulation. In this study, we hypothesized that HTT repeat sizes < 36 are associated with metabolite levels, possibly mediated through reduced BMI. We pooled data from three European cohorts (n = 10 228) with genotyped HTT CAG repeat size and metabolomic measurements. All 145 metabolites were measured on the same targeted platform in all studies. Multilevel mixed-effects analysis using the CAG repeat size in HTT identified 67 repeat size metabolite associations. Overall, the metabolomic profile associated with larger CAG repeat sizes in HTT were unfavorable-similar to those of higher risk of coronary artery disease and type 2 diabetes-and included elevated levels of amino acids, fatty acids, low-density lipoprotein (LDL)-, very low-density lipoprotein- and intermediate density lipoprotein (IDL)-related metabolites while with decreased levels of very large high-density lipoprotein (HDL)-related metabolites. Furthermore, the associations of 50 metabolites, in particular, specific very large HDL-related metabolites, were mediated by lower BMI. However, no mediation effect was found for 17 metabolites related to LDL and IDL. In conclusion, our findings indicate that large non-pathogenic CAG repeat sizes in HTT are associated with an unfavorable metabolomic profile despite their association with a lower BMI.
Collapse
Affiliation(s)
- Tariq O Faquih
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| | - N Ahmad Aziz
- Population Health Sciences, German Center for Neurodegenerative Diseases (DZNE), Bonn 53175, Germany
- Department of Neurology, Bonn University Hospital, Bonn 53175, Germany
| | - Sarah L Gardiner
- Department of Neurology, Amsterdam UMC, Amsterdam 1080 HZ, The Netherlands
| | - Ruifang Li-Gao
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
- Metabolon, Inc., Morrisville, NC 27560, USA
| | - Renée de Mutsert
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| | - Yuri Milaneschi
- Department of Psychiatry, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam 1081 HZ, The Netherlands
- Amsterdam Public Health, Mental Health Program, Amsterdam 1081 HZ, The Netherlands
- Amsterdam Neuroscience, Mood, Anxiety, Psychosis, Sleep & Stress Program, Amsterdam 1081 HZ, The Netherlands
- Amsterdam Neuroscience, Complex Trait Genetics, Amsterdam 1081 HV, The Netherlands
| | - Stella Trompet
- Department of Internal Medicine, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| | - J Wouter Jukema
- Department of Cardiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| | - Frits R Rosendaal
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| | - Astrid van Hylckama Vlieg
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| | - Ko Willems van Dijk
- Department of Human Genetics, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
- Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
- Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| | - Dennis O Mook-Kanamori
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
- Department of Public Health and Primary Care, Leiden University Medical Center, Leiden 2300 RC, The Netherlands
| |
Collapse
|
4
|
P Silvestre M, Fogelholm M, Alves M, Papoila A, Adam T, Liu A, Brand-Miller J, Martinez JA, Westerterp-Plantenga M, Handjieva-Darlenska T, Macdonald IA, Zhu R, Jalo E, Muirhead R, Carretero SN, Handjiev S, Taylor MA, Raben A, Poppitt SD. Differences between HbA 1c and glucose-related variables in predicting weight loss and glycaemic changes in individuals with overweight and hyperglycaemia - The PREVIEW trial. Clin Nutr 2023; 42:636-643. [PMID: 36933350 DOI: 10.1016/j.clnu.2023.02.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Revised: 02/12/2023] [Accepted: 02/28/2023] [Indexed: 03/08/2023]
Abstract
AIMS To examine the differences between HbA1c and glucose related variables in predicting weight loss and glycaemic changes following 8 weeks of low energy diet (LED) in individuals with overweight and hyperglycaemia. RESEARCH DESIGN AND METHODS 2178 individuals with ADA-defined pre-diabetes - impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) - who started an 8 week LED weight loss diet, were included in this analysis. Participants were enrolled in the PREVIEW (PREVention of diabetes through lifestyle interventions and population studies In Europe and around the World) clinical trial. Multivariable linear mixed effects regression models and generalised additive mixed effect logistic models were used. RESULTS Only 1 in 3 participants (33%) had HbA1c levels defined as pre-diabetes. Neither baseline HbA1c, IFG or IGT were associated with body weight change at 8 weeks. Higher baseline body weight, baseline fasting insulin and weight loss predicted normalisation of fasting plasma glucose (FPG), whilst higher baseline fasting insulin, C-reactive protein (hsCRP) and older age predicted normalisation of HbA1c. Additionally, male sex and higher baseline BMI, body fat and energy intake were positively associated with weight loss, whereas greater age and higher HDL-cholesterol predicted less weight loss. CONCLUSIONS Whilst neither HbA1c nor fasting glucose predicts short-term weight loss success, both may impact the metabolic response to rapid weight loss. We propose a role of inflammation versus total body adiposity since these variables are independent predictors of the normalisation of HbA1c and fasting glucose, respectively.
Collapse
Affiliation(s)
- Marta P Silvestre
- Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand; CINTESIS, NOVA Medical School, NMS, Universidade Nova de Lisboa, 1169-056, Lisboa, Portugal.
| | - Mikael Fogelholm
- Department of Food and Nutrition, University of Helsinki, Helsinki, Finland
| | - Marta Alves
- CEAUL, NOVA Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056, Lisboa, Portugal
| | - Ana Papoila
- CEAUL, NOVA Medical School/Faculdade de Ciências Médicas, Universidade Nova de Lisboa, 1169-056, Lisboa, Portugal
| | - Tanja Adam
- Department of Nutrition and Movement Sciences, NUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands
| | - Amy Liu
- Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand
| | - Jennie Brand-Miller
- School of Life and Environmental Sciences and Charles Perkins Centre, University of Sydney, Sydney, Australia
| | - J Alfredo Martinez
- Center for Nutrition Research, University of Navarra, 31008, Pamplona, Spain
| | - Margriet Westerterp-Plantenga
- Department of Nutrition and Movement Sciences, NUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands
| | | | - Ian A Macdonald
- MRC/ARUK Centre for Musculoskeletal Ageing Research, National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, United Kingdom
| | - Ruixin Zhu
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark
| | - Elli Jalo
- Department of Food and Nutrition, University of Helsinki, Helsinki, Finland
| | - Roslyn Muirhead
- School of Life and Environmental Sciences and Charles Perkins Centre, University of Sydney, Sydney, Australia
| | - Santiago Navas Carretero
- Center for Nutrition Research, University of Navarra, 31008, Pamplona, Spain; CIBERObn, Instituto de Salud Carlos III, Madrid, Spain
| | - Svetoslav Handjiev
- Department of Pharmacology and Toxicology, Medical University of Sofia, Sofia, Bulgaria
| | - Moira A Taylor
- NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust and University of Nottingham, The David Greenfield Human Physiology Unit, Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK
| | - Anne Raben
- Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark; Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark
| | - Sally D Poppitt
- Human Nutrition Unit, School of Biological Sciences, Department of Medicine, University of Auckland, Auckland, New Zealand
| |
Collapse
|
5
|
Effects of dietary and exercise treatments on HDL subclasses in lactating women with overweight and obesity: a secondary analysis of a randomised controlled trial. Br J Nutr 2022; 128:2105-2114. [PMID: 35067237 PMCID: PMC9661371 DOI: 10.1017/s0007114522000241] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Childbearing decreases HDL-cholesterol, potentially contributing to the increased risk of CVD in parous women. Large HDL particles (HDL-P) are associated with lower risk of CVD. In this secondary analysis of a randomised controlled trial, we investigated the effects of 12-week dietary and exercise treatments on HDL-P subclass concentration, size and apoA1 in lactating women with overweight/obesity. At 10-14 weeks postpartum, 68 women with pre-pregnant BMI 25-35 kg/m2 were randomised to four groups using 2 × 2 factorial design: (1) dietary treatment for weight loss; (2) exercise treatment; (3) both treatments and (4) no treatment. Lipoprotein subclass profiling by NMR spectroscopy was performed in serum at randomisation and after 3 and 12 months, and the results analysed with two-way ANCOVA. Lipid concentrations decline naturally postpartum. At 3 months (5-6 months postpartum), both diet (P = 0·003) and exercise (P = 0·008) reduced small HDL-P concentration. Concurrently, exercise limited the decline in very large HDL-P (P = 0·002) and the effect was still significant at 12 months (15 months postpartum) (P = 0·041). At 12 months, diet limited the decline in very large HDL-P (P = 0·005), large HDL-P (P = 0·001) and apoA1 (P = 0·002) as well as HDL size (P = 0·002). The dietary treatment for weight loss and the exercise treatment both showed effects on HDL-P subclasses in lactating women with overweight and obesity possibly associated with lower CVD risk. The dietary treatment had more effects than the exercise treatment at 12 months, likely associated with a 10 % weight loss.
Collapse
|
6
|
Schutte S, Esser D, Siebelink E, Michielsen CJR, Daanje M, Matualatupauw JC, Boshuizen HC, Mensink M, Afman LA, Esser D, Siebelink E, Fick H, Grootte Bromhaar MM, Wang Y, de Bruijn SEM, Mars M, Meijerink J, Mensink M, Afman LA, Feskens EJM, Müller M. Diverging metabolic effects of 2 energy-restricted diets differing in nutrient quality: a 12-week randomized controlled trial in subjects with abdominal obesity. Am J Clin Nutr 2022; 116:132-150. [PMID: 35102369 PMCID: PMC9257474 DOI: 10.1093/ajcn/nqac025] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Accepted: 01/24/2022] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Despite the established relation between energy restriction (ER) and metabolic health, the most beneficial nutrient composition of a weight-loss diet is still a subject of debate. OBJECTIVES The aim of the study was to examine the additional effects of nutrient quality on top of ER. METHODS A parallel-designed, 12-week 25% ER dietary intervention study was conducted (clinicaltrials.gov: NCT02194504). Participants aged 40-70 years with abdominal obesity were randomized over 3 groups: a 25% ER high-nutrient-quality diet (n = 40); a 25% ER low-nutrient-quality diet (n = 40); or a habitual diet (n = 30). Both ER diets were nutritionally adequate, and the high-nutrient-quality ER diet was enriched in MUFAs, n-3 PUFAs, fiber, and plant protein and reduced in fructose. Before and after the intervention, intrahepatic lipids, body fat distribution, fasting and postprandial responses to a mixed-meal shake challenge test of cardiometabolic risk factors, lipoproteins, vascular measurements, and adipose tissue transcriptome were assessed. RESULTS The high-nutrient-quality ER diet (-8.4 ± 3.2) induced 2.1 kg more weight loss (P = 0.007) than the low-nutrient-quality ER diet (-6.3 ± 3.9), reduced fasting serum total cholesterol (P = 0.014) and plasma triglycerides (P < 0.001), promoted an antiatherogenic lipoprotein profile, and induced a more pronounced decrease in adipose tissue gene expression of energy metabolism pathways than the low-quality ER diet. Explorative analyses showed that the difference in weight loss between the two ER diets was specifically present in insulin-sensitive subjects (HOMA-IR ≤ 2.5), in whom the high-nutrient-quality diet induced 3.9 kg more weight loss than the low-nutrient-quality diet. CONCLUSIONS A high-nutrient-quality 25% ER diet is more beneficial for cardiometabolic health than a low-nutrient-quality 25% ER diet. Overweight, insulin-sensitive subjects may benefit more from a high- than a low-nutrient-quality ER diet with respect to weight loss, due to potential attenuation of glucose-induced lipid synthesis in adipose tissue.
Collapse
Affiliation(s)
- Sophie Schutte
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | - Diederik Esser
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | - Els Siebelink
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | - Charlotte J R Michielsen
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | - Monique Daanje
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | - Juri C Matualatupauw
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | - Hendriek C Boshuizen
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | - Marco Mensink
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | | | - The Wageningen Belly Fat Study team
SchutteSophiePhDDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsEsserDiederikPhDDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsSiebelinkElsBScSenior Research DieticianDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsFickHenriëtteBScCoordinator Human ResearchDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsGrootte BromhaarMechteld MBScLaboratory Technician Human ResearchDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsWangYaPhDDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlandsde BruijnSuzanne E MPhDDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsMarsMonicaPhDAssociate ProfessorDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsMeijerinkJocelijnPhDAssistant ProfessorDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlandshttps://orcid.org/0000-0002-9725-5709MensinkMarcoPhD, MDAssistant ProfessorDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlandshttps://orcid.org/0000-0002-7939-6217AfmanLydia APhDAssociate ProfessorDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsFeskensEdith J MPhDProfessorDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The NetherlandsMüllerMichaelPhDDirector of the Food and Metabolic Health Alliance & Professor at the University of East Anglia, Former Professor at Wageningen UniversityDivision of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health, Wageningen, The Netherlands
| | - Diederik Esser
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Els Siebelink
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Henriëtte Fick
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Mechteld M Grootte Bromhaar
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Ya Wang
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Suzanne E M de Bruijn
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Monica Mars
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Jocelijn Meijerink
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Marco Mensink
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Lydia A Afman
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Edith J M Feskens
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | - Michael Müller
- Division of Human Nutrition and Health, Wageningen University, Division of Human Nutrition and Health , Wageningen, The Netherlands
| | | |
Collapse
|
7
|
Lipidomic Signatures of Changes in Adiposity: A Large Prospective Study of 5849 Adults from the Australian Diabetes, Obesity and Lifestyle Study. Metabolites 2021; 11:metabo11090646. [PMID: 34564462 PMCID: PMC8471381 DOI: 10.3390/metabo11090646] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Revised: 09/19/2021] [Accepted: 09/19/2021] [Indexed: 12/28/2022] Open
Abstract
Lipid metabolism is tightly linked to adiposity. Comprehensive lipidomic profiling offers new insights into the dysregulation of lipid metabolism in relation to weight gain. Here, we investigated the relationship of the human plasma lipidome and changes in waist circumference (WC) and body mass index (BMI). Adults (2653 men and 3196 women), 25–95 years old who attended the baseline survey of the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) and the 5-year follow-up were enrolled. A targeted lipidomic approach was used to quantify 706 distinct molecular lipid species in the plasma samples. Multiple linear regression models were used to examine the relationship between the baseline lipidomic profile and changes in WC and BMI. Metabolic scores for change in WC were generated using a ridge regression model. Alkyl-diacylglycerol such as TG(O-50:2) [NL-18:1] displayed the strongest association with change in WC (β-coefficient = 0.125 cm increment per SD increment in baseline lipid level, p = 2.78 × 10−11. Many lipid species containing linoleate (18:2) fatty acids were negatively associated with both WC and BMI gain. Compared to traditional models, multivariate models containing lipid species identify individuals at a greater risk of gaining WC: top quintile relative to bottom quintile (odds ratio, 95% CI = 5.4, 3.8–6.6 for women and 2.3, 1.7–3.0 for men). Our findings define metabolic profiles that characterize individuals at risk of weight gain or WC increase and provide important insight into the biological role of lipids in obesity.
Collapse
|
8
|
Tang X, Zhang H, Zhao Y, Lei F, Liu Q, Hu D, Li G, Song G. Transition Patterns of Weight Status and Their Predictive Lipid Markers Among Chinese Adults: A Longitudinal Cohort Study Using the Multistate Markov Model. Diabetes Metab Syndr Obes 2021; 14:2661-2671. [PMID: 34163194 PMCID: PMC8215687 DOI: 10.2147/dmso.s308913] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/01/2021] [Accepted: 05/21/2021] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Obesity is well recognized as a risk factor for cardiometabolic diseases. The development of obesity is a dynamic process that can be described as a multistate process with an emphasis on transitions between weight states. However, it is still unclear what convenient biomarkers predict transitions between weight states. The aim of this study was to show the dynamic nature of weight status in adults stratified by age and sex and to explore blood markers of metabolic syndrome (MetS) that predict transitions between weight states. METHODS This study involved 9795 individuals aged 18 to 56 at study entry who underwent at least two health check-ups in the eight-year period of study in the health check-up centre of our institution. Weight, height and biochemical indices were measured at each check-up. The participants were divided into four groups based on age and sex (young male, middle-aged male, young female and middle-aged female groups). A multistate Markov model containing 3 states (healthy weight, overweight and obesity) was adopted to study the longitudinal weight data. RESULTS Young people were more likely to transit between weight states than middle-aged people, and middle-aged people were more resistant to recover from worse states. The mean sojourn time in obesity was greatest in the middle-aged male group (6.23 years), and the predicted rate of obesity beginning with healthy weight was greatest in the young male group (13.7%). In multivariate models, age group and triglyceride (TG) and high-density lipoprotein cholesterol (HDL) levels were significant for specific transitions in females, whereas age group and HDL levels were significant in males. In females, if HDL levels increased 1 mmol/L, the probability of progression from healthy weight to overweight decreased by 37.0% (HR= 0.63), and the probabilities of recovery (overweight to healthy weight and obesity to overweight) increased by 62.0% (HR= 1.62) and 1.23-fold (HR= 2.23), respectively. In males, if TG levels increased 1 mmol/L, the risk of progression from healthy weight to overweight increased by 24.0% (HR= 1.24). Each unit increase in HDL levels was associated with a 0.99-fold (HR= 1.99) increase in the chance of recovery from overweight to healthy weight and with a 0.37-fold (HR= 0.63) decrease in the risk of progression from healthy weight to overweight. CONCLUSION The weight status of young people was less stable than that of middle-aged people. Males were more likely to become overweight and more resistant to recover from worse states than females. Young males with healthy weight were more likely to develop obesity than other healthy weight groups. Blood lipid levels, especially HDL, were predictors of weight transitions in adults. Prevention and intervention measures should be applied early.
Collapse
Affiliation(s)
- Xiao Tang
- Department of Health Statistics, School of Public Health, Dalian Medical University, Dalian City, Liaoning Province, 116044, People’s Republic of China
| | - Hongya Zhang
- Department of Health Statistics, School of Public Health, Dalian Medical University, Dalian City, Liaoning Province, 116044, People’s Republic of China
| | - Yanxiang Zhao
- Department of Mathematics, George Washington University, Washington, DC, USA
| | - Fang Lei
- Department of Health Statistics, School of Public Health, Dalian Medical University, Dalian City, Liaoning Province, 116044, People’s Republic of China
| | - Qigui Liu
- Department of Health Statistics, School of Public Health, Dalian Medical University, Dalian City, Liaoning Province, 116044, People’s Republic of China
| | - Dongmei Hu
- Department of Health Statistics, School of Public Health, Dalian Medical University, Dalian City, Liaoning Province, 116044, People’s Republic of China
| | - Guorong Li
- Department of Health Statistics, School of Public Health, Dalian Medical University, Dalian City, Liaoning Province, 116044, People’s Republic of China
| | - Guirong Song
- Department of Health Statistics, School of Public Health, Dalian Medical University, Dalian City, Liaoning Province, 116044, People’s Republic of China
- Correspondence: Guirong Song Department of Health Statistics, School of Public Health, Dalian Medical University, No. 9 South Road, Lvshun District, Dalian City, Liaoning Province, 116044, People’s Republic of ChinaTel +86-411-86110328 Email
| |
Collapse
|
9
|
Choline Intake as Supplement or as a Component of Eggs Increases Plasma Choline and Reduces Interleukin-6 without Modifying Plasma Cholesterol in Participants with Metabolic Syndrome. Nutrients 2020; 12:nu12103120. [PMID: 33066009 PMCID: PMC7600433 DOI: 10.3390/nu12103120] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2020] [Revised: 10/01/2020] [Accepted: 10/06/2020] [Indexed: 12/25/2022] Open
Abstract
Metabolic syndrome (MetS) is characterized by low-grade inflammation and insulin resistance, which increase the risk of heart disease. Eggs have numerous nutrients including choline, carotenoids, and fat-soluble vitamins that may protect against these conditions. Egg phosphatidylcholine (PC) is a major contributor of dietary choline in the American diet. However, uncertainty remains regarding eggs due to their high concentration of cholesterol. In this study, we evaluated the effect of two sources of choline, whole eggs (a source of PC) and a choline supplement (choline bitartrate, CB), on plasma lipids, glucose, insulin resistance, and inflammatory biomarkers. We recruited 23 subjects with MetS to participate in this randomized cross-over intervention. After a 2-week washout, with no choline intake, participants were randomly allocated to consume three eggs/day or CB (~400 mg choline/d for both) for 4 weeks. After a 3-week washout period, they were allocated to the alternate treatment. Dietary records indicated higher concentrations of vitamin E and selenium during the egg period (p < 0.01). Interestingly, there were no changes in plasma total, low density lipoprotein (LDL)- or high density lipoprotein (HDL)-cholesterol, triglycerides, or glucose, compared either to baseline or between treatments. In contrast, interleukin-6 was reduced, with both sources of choline compared to baseline, while eggs also had an effect on lowering C-reactive protein, insulin, and insulin resistance compared to baseline. This study demonstrates that in a MetS population, intake of three eggs per day does not increase plasma LDL cholesterol, and has additional benefits on biomarkers of disease compared to a choline supplement, possibly due to the presence of other antioxidants in eggs.
Collapse
|
10
|
Crawford HC, Wallace MB, Storz P. Early detection and imaging strategies to reveal and target developing pancreatic cancer. Expert Rev Anticancer Ther 2020; 20:81-83. [PMID: 31986932 DOI: 10.1080/14737140.2020.1720654] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Howard C Crawford
- Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA
| | | | - Peter Storz
- Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville, FL, USA
| |
Collapse
|
11
|
Hausmann J, Waechtershaeuser A, Behnken I, Aksan A, Blumenstein I, Brenner M, Loitsch SM, Stein J. The role of adipokines in the improvement of diabetic and cardiovascular risk factors within a 52-week weight-loss programme for obesity. Obes Res Clin Pract 2019; 13:440-447. [PMID: 31591082 DOI: 10.1016/j.orcp.2019.09.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/11/2019] [Revised: 09/17/2019] [Accepted: 09/23/2019] [Indexed: 01/01/2023]
|
12
|
Sah RP, Sharma A, Nagpal S, Patlolla SH, Sharma A, Kandlakunta H, Anani V, Angom RS, Kamboj AK, Ahmed N, Mohapatra S, Vivekanandhan S, Philbrick KA, Weston A, Takahashi N, Kirkland J, Javeed N, Matveyenko A, Levy MJ, Mukhopadhyay D, Chari ST. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma. Gastroenterology 2019; 156:1742-1752. [PMID: 30677401 PMCID: PMC6475474 DOI: 10.1053/j.gastro.2019.01.039] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2018] [Revised: 12/13/2018] [Accepted: 01/11/2019] [Indexed: 12/29/2022]
Abstract
BACKGROUND & AIMS Identifying metabolic abnormalities that occur before pancreatic ductal adenocarcinoma (PDAC) diagnosis could increase chances for early detection. We collected data on changes in metabolic parameters (glucose, serum lipids, triglycerides; total, low-density, and high-density cholesterol; and total body weight) and soft tissues (abdominal subcutaneous fat [SAT], adipose tissue, visceral adipose tissue [VAT], and muscle) from patients 5 years before the received a diagnosis of PDAC. METHODS We collected data from 219 patients with a diagnosis of PDAC (patients) and 657 healthy individuals (controls) from the Rochester Epidemiology Project, from 2000 through 2015. We compared metabolic profiles of patients with those of age- and sex-matched controls, constructing temporal profiles of fasting blood glucose, serum lipids including triglycerides, cholesterol profiles, and body weight and temperature for 60 months before the diagnosis of PDAC (index date). To construct the temporal profile of soft tissue changes, we collected computed tomography scans from 68 patients, comparing baseline (>18 months before diagnosis) areas of SAT, VAT, and muscle at L2/L3 vertebra with those of later scans until time of diagnosis. SAT and VAT, isolated from healthy individuals, were exposed to exosomes isolated from PDAC cell lines and analyzed by RNA sequencing. SAT was collected from KRAS+/LSLG12D P53flox/flox mice with PDACs, C57/BL6 (control) mice, and 5 patients and analyzed by histology and immunohistochemistry. RESULTS There were no significant differences in metabolic or soft tissue features of patients vs controls until 30 months before PDAC diagnosis. In the 30 to 18 months before PDAC diagnosis (phase 1, hyperglycemia), a significant proportion of patients developed hyperglycemia, compared with controls, without soft tissue changes. In the 18 to 6 months before PDAC diagnosis (phase 2, pre-cachexia), patients had significant increases in hyperglycemia and decreases in serum lipids, body weight, and SAT, with preserved VAT and muscle. In the 6 to 0 months before PDAC diagnosis (phase 3, cachexia), a significant proportion of patients had hyperglycemia compared with controls, and patients had significant reductions in all serum lipids, SAT, VAT, and muscle. We believe the patients had browning of SAT, based on increases in body temperature, starting 18 months before PDAC diagnosis. We observed expression of uncoupling protein 1 (UCP1) in SAT exposed to PDAC exosomes, SAT from mice with PDACs, and SAT from all 5 patients but only 1 of 4 controls. CONCLUSIONS We identified 3 phases of metabolic and soft tissue changes that precede a diagnosis of PDAC. Loss of SAT starts 18 months before PDAC identification, and is likely due to browning. Overexpression of UCP1 in SAT might be a biomarker of early-stage PDAC, but further studies are needed.
Collapse
MESH Headings
- Adipocytes/metabolism
- Adipocytes/pathology
- Animals
- Blood Glucose/metabolism
- Body Temperature
- Body Weight
- Cachexia/etiology
- Carcinoma, Pancreatic Ductal/blood
- Carcinoma, Pancreatic Ductal/complications
- Carcinoma, Pancreatic Ductal/diagnosis
- Carcinoma, Pancreatic Ductal/genetics
- Case-Control Studies
- Cells, Cultured
- Cholesterol, HDL/blood
- Cholesterol, LDL/blood
- Exosomes
- Humans
- Hyperglycemia/blood
- Hyperglycemia/etiology
- Intra-Abdominal Fat/diagnostic imaging
- Intra-Abdominal Fat/pathology
- Mice
- Middle Aged
- Muscle, Skeletal/diagnostic imaging
- Pancreatic Neoplasms/blood
- Pancreatic Neoplasms/complications
- Pancreatic Neoplasms/diagnosis
- Pancreatic Neoplasms/genetics
- RNA, Messenger/metabolism
- Retrospective Studies
- Subcutaneous Fat, Abdominal/diagnostic imaging
- Subcutaneous Fat, Abdominal/pathology
- Time Factors
- Tomography, X-Ray Computed
- Triglycerides/blood
- Uncoupling Protein 1/genetics
- Up-Regulation
Collapse
Affiliation(s)
- Raghuwansh P Sah
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Ayush Sharma
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Sajan Nagpal
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Sri Harsha Patlolla
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Anil Sharma
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, Florida
| | - Harika Kandlakunta
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Vincent Anani
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Ramcharan Singh Angom
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, Florida
| | - Amrit K Kamboj
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Nazir Ahmed
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Sonmoon Mohapatra
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | - Sneha Vivekanandhan
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, Florida
| | | | - Alexander Weston
- Department of Radiology Informatics, Mayo Clinic, Rochester, Minnesota
| | | | - James Kirkland
- Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota
| | - Naureen Javeed
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota
| | - Aleksey Matveyenko
- Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota
| | - Michael J Levy
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
| | | | - Suresh T Chari
- Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.
| |
Collapse
|
13
|
The Metabolomic Signatures of Weight Change. Metabolites 2019; 9:metabo9040067. [PMID: 30987392 PMCID: PMC6523676 DOI: 10.3390/metabo9040067] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2019] [Revised: 03/18/2019] [Accepted: 04/03/2019] [Indexed: 12/17/2022] Open
Abstract
Obesity represents a major health concern, not just in the West but increasingly in low and middle income countries. In order to develop successful strategies for losing weight, it is essential to understand the molecular pathogenesis of weight change. A number of pathways, implicating oxidative stress but also the fundamental regulatory of insulin, have been implicated in weight gain and in the regulation of energy expenditure. In addition, a considerable body of work has highlighted the role of metabolites generated by the gut microbiome, in particular short chain fatty acids, in both processes. The current review provides a brief understanding of the mechanisms underlying the associations of weight change with changes in lipid and amino acid metabolism, energy metabolism, dietary composition and insulin dynamics, as well as the influence of the gut microbiome. The changes in metabolomic profiles and the models outlined can be used as an accurate predictor for obesity and obesity related disorders.
Collapse
|
14
|
Woudberg NJ, Lecour S, Goedecke JH. HDL Subclass Distribution Shifts with Increasing Central Adiposity. J Obes 2019; 2019:2107178. [PMID: 30863631 PMCID: PMC6378000 DOI: 10.1155/2019/2107178] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 11/05/2018] [Accepted: 01/08/2019] [Indexed: 02/07/2023] Open
Abstract
Although cross-sectional studies have shown that obesity is associated with lower concentrations of large high-density lipoprotein (HDL) subclasses, it is unknown if changes in HDL subclasses are related to changes in body fat and its distribution over time. We therefore assessed changes in HDL subclass distribution over a 5.5-year free-living follow-up period in 24 black South African women. At baseline and follow-up, body composition and body fat distribution were measured using anthropometry, dual X-ray absorptiometry, and computerized tomography. HDL subclass distribution was quantified using Lipoprint®. Over the 5.5-year follow-up period, body fat (+17.3 ± 4.5 kg, p < 0.05) and trunk fat mass (+7.4 ± 1.9%, % fat mass, FM, p < 0.05) increased, while leg fat mass (-2.53 ± 0.56%, % FM, p < 0.001) and the distribution of large (-6.43 ± 2.12%, p < 0.05) HDL subclasses decreased. A percentage decrease in large HDL subclasses was associated with a percentage increase in central fat mass (visceral adipose tissue (VAT) area, p < 0.05) and a percentage decrease in peripheral fat mass (leg fat mass). These preliminary findings suggest that a relative redistribution of body fat from the periphery to the abdominal region were associated with a decrease HDL subclass size in black South African women and provide a novel link between body fat distribution and lipidology in this population.
Collapse
Affiliation(s)
- Nicholas J. Woudberg
- Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Sandrine Lecour
- Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
| | - Julia H. Goedecke
- Non-Communicable Diseases Research Unit, South African Medical Research Council, Parow Valley, Cape Town, South Africa
- Division of Exercise Science and Sports Medicine, Department of Human Biology, University of Cape Town, Cape Town, South Africa
| |
Collapse
|
15
|
Pichler G, Amigo N, Tellez-Plaza M, Pardo-Cea M, Dominguez-Lucas A, Marrachelli V, Monleon D, Martin-Escudero J, Ascaso J, Chaves F, Carmena R, Redon J. LDL particle size and composition and incident cardiovascular disease in a South-European population: The Hortega-Liposcale Follow-up Study. Int J Cardiol 2018; 264:172-178. [DOI: 10.1016/j.ijcard.2018.03.128] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 03/13/2018] [Accepted: 03/27/2018] [Indexed: 11/30/2022]
|
16
|
Gómez-Martin JM, Balsa JA, Aracil E, Cuadrado-Ayuso M, Rosillo M, De la Peña G, Lasunción MA, Escobar-Morreale HF, Botella-Carretero JI. Beneficial changes on plasma apolipoproteins A and B, high density lipoproteins and oxidized low density lipoproteins in obese women after bariatric surgery: comparison between gastric bypass and sleeve gastrectomy. Lipids Health Dis 2018; 17:145. [PMID: 29925393 PMCID: PMC6011580 DOI: 10.1186/s12944-018-0794-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Accepted: 05/31/2018] [Indexed: 12/11/2022] Open
Abstract
Background The beneficial effects in lipid profiles after obesity surgery might be associated with the decrease in cardiovascular risk. However, direct comparison between different surgical techniques has not been extensively performed. Methods In the present study we compare 20 obese women submitted to laparoscopic Roux en Y gastric bypass (RYGB) with 20 women submitted to sleeve gastrectomy (SG). Twenty control women matched for age and baseline cardiovascular risk were also included. Both patients and controls were followed up for 1 year after surgery or conventional treatment with diet and exercise, respectively. Lipid profiles were measured at baseline, 6 and 12 months later. Carotid intima-media thickness was measured by ultrasonography at baseline and at the end of the study. Results Women submitted to bariatric surgery showed a decrease in total cholesterol, triglycerides, oxidized-LDL and ApoB, and an increase in HDL and ApoA concentrations that occurred regardless of the surgical procedure. LDL concentrations, however, decreased only after RYGB whereas Lp(a) showed no changes. We did not observe any correlation between the changes in serum lipid concentrations and those in carotid intima-media thickness. Conclusions Sleeve gastrectomy and gastric bypass induce a similar beneficial effect on serum lipids in women with high cardiovascular risk 1 year after surgery.
Collapse
Affiliation(s)
- J M Gómez-Martin
- Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Carretera de Colmenar Km. 9.1, 28034, Madrid, Spain
| | - J A Balsa
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain.,Department of Endocrinology and Nutrition, Hospital Infanta Sofía & Universidad Europea, Madrid, Spain
| | - E Aracil
- Department of Vascular Surgery, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034, Madrid, Spain
| | - M Cuadrado-Ayuso
- Department of General and Gastrointestinal Surgery, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034, Madrid, Spain
| | - M Rosillo
- Department of Clinical Biochemistry, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034, Madrid, Spain
| | - G De la Peña
- Department of Biochemistry Research, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034, Madrid, Spain.,Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain
| | - M A Lasunción
- Department of Biochemistry Research, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), 28034, Madrid, Spain.,Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain
| | - H F Escobar-Morreale
- Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Carretera de Colmenar Km. 9.1, 28034, Madrid, Spain.,Universidad de Alcalá & Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Madrid, Spain
| | - J I Botella-Carretero
- Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal & Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Carretera de Colmenar Km. 9.1, 28034, Madrid, Spain. .,Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Madrid, Spain.
| |
Collapse
|
17
|
Talbot CPJ, Plat J, Joris PJ, Konings M, Kusters YHAM, Schalkwijk CG, Ritsch A, Mensink RP. HDL cholesterol efflux capacity and cholesteryl ester transfer are associated with body mass, but are not changed by diet-induced weight loss: A randomized trial in abdominally obese men. Atherosclerosis 2018; 274:23-28. [PMID: 29747087 DOI: 10.1016/j.atherosclerosis.2018.04.029] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 04/04/2018] [Accepted: 04/24/2018] [Indexed: 10/17/2022]
Abstract
BACKGROUND AND AIMS Obesity is associated with a lower HDL-mediated cholesterol efflux from macrophages and a higher CETP (cholesteryl ester transfer protein) activity, but effects of weight loss are not clear. In addition, associations with visceral and subcutaneous adipose tissue are not known. We therefore investigated effects of diet-induced weight loss on HDL-mediated cholesterol efflux and cholesterol ester (CE) transfer in abdominally obese men. Differences between normal-weight and abdominally obese men were also examined. METHODS Twenty-five apparently healthy, normal-weight men (waist circumference: <94 cm) and 52 abdominally obese men (waist circumference: 102-110 cm) were included. Abdominally obese subjects were randomly allocated to a dietary weight-loss intervention group or a no-weight loss control group. Individuals from the intervention group followed a very-low-calorie diet for 6 weeks to obtain a waist circumference below 102 cm, followed by a 2-week weight-stable period. Cholesterol efflux was measured in BODIPY-labeled murine J774 macrophages. CE transfer was measured by quantifying the transfer of CE from radiolabeled exogenous HDL to apoB-containing lipoproteins. RESULTS Cholesterol efflux capacity was 9 percentage point (pp) lower in abdominally obese than in normal-weight men (p≤0.001), while CE transfer was 5 pp higher (p≤0.01). Diet-induced weight-loss of 10.3 kg did not change cholesterol efflux and CE transfer. In addition, stepwise regression analysis did not suggest that the different fat depots are differently related to efflux capacity and CE transfer. CONCLUSIONS After a 2-week weight-stable period, dietary weight loss of 10 kg did not improve ABCA1-mediated cholesterol efflux and CE transfer in abdominally obese men.
Collapse
Affiliation(s)
- Charlotte P J Talbot
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands.
| | - Jogchum Plat
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| | - Peter J Joris
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| | - Maurice Konings
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| | - Yvo H A M Kusters
- Department of Internal Medicine, CARIM (School for Cardiovascular Diseases), Maastricht University Medical Center, Maastricht, Netherlands
| | - Casper G Schalkwijk
- Department of Internal Medicine, CARIM (School for Cardiovascular Diseases), Maastricht University Medical Center, Maastricht, Netherlands
| | | | - Ronald P Mensink
- Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| |
Collapse
|
18
|
Khan AA, Mundra PA, Straznicky NE, Nestel PJ, Wong G, Tan R, Huynh K, Ng TW, Mellett NA, Weir JM, Barlow CK, Alshehry ZH, Lambert GW, Kingwell BA, Meikle PJ. Weight Loss and Exercise Alter the High-Density Lipoprotein Lipidome and Improve High-Density Lipoprotein Functionality in Metabolic Syndrome. Arterioscler Thromb Vasc Biol 2018; 38:438-447. [DOI: 10.1161/atvbaha.117.310212] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2017] [Accepted: 12/19/2017] [Indexed: 12/25/2022]
Affiliation(s)
- Anmar A. Khan
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Piyushkumar A. Mundra
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Nora E. Straznicky
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Paul J. Nestel
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Gerard Wong
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Ricardo Tan
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Kevin Huynh
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Theodore W. Ng
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Natalie A. Mellett
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Jacquelyn M. Weir
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Christopher K. Barlow
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Zahir H. Alshehry
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Gavin W. Lambert
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Bronwyn A. Kingwell
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| | - Peter J. Meikle
- From the Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (A.A.K., P.A.M., N.E.S., P.J.N., G.W., R.T., K.H., T.W.N., N.A.M., J.M.W., C.K.B., Z.H.A., G.W.L., B.A.K., P.J.M.); Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia (A.A.K., B.A.K., P.J.M.); Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia (A.A.K.); King Fahad Medical City, Riyadh, Saudi Arabia (Z.H.A.); and School of Biomedical Sciences,
| |
Collapse
|
19
|
Talbot CP, Plat J, Ritsch A, Mensink RP. Determinants of cholesterol efflux capacity in humans. Prog Lipid Res 2018; 69:21-32. [PMID: 29269048 DOI: 10.1016/j.plipres.2017.12.001] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Revised: 12/09/2017] [Accepted: 12/11/2017] [Indexed: 12/26/2022]
|
20
|
Herzig KH, Leppäluoto J, Jokelainen J, Meugnier E, Pesenti S, Selänne H, Mäkelä KA, Ahola R, Jämsä T, Vidal H, Keinänen-Kiukaanniemi S. Low level activity thresholds for changes in NMR biomarkers and genes in high risk subjects for Type 2 Diabetes. Sci Rep 2017; 7:11267. [PMID: 28924247 PMCID: PMC5603534 DOI: 10.1038/s41598-017-09753-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 07/28/2017] [Indexed: 01/26/2023] Open
Abstract
Our objectives were to determine if there are quantitative associations between amounts and intensities of physical activities (PA) on NMR biomarkers and changes in skeletal muscle gene expressions in subjects with high risk for type 2 diabetes (T2D) performing a 3-month PA intervention. We found that PA was associated with beneficial biomarker changes in a factor containing several VLDL and HDL subclasses and lipids in principal component analysis (P = <0.01). Division of PA into quartiles demonstrated significant changes in NMR biomarkers in the 2nd - 4th quartiles compared to the 1st quartile representing PA of less than 2850 daily steps (P = 0.0036). Mediation analysis of PA-related reductions in lipoproteins showed that the effects of PA was 4-15 times greater than those of body weight or fat mass reductions. In a subset study in highly active subjects' gene expressions of oxidative fiber markers, Apo D, and G0/G1 Switch Gene 2, controlling insulin signaling and glucose metabolism were significantly increased. Slow walking at speeds of 2-3 km/h exceeding 2895 steps/day attenuated several circulating lipoprotein lipids. The effects were mediated rather by PA than body weight or fat loss. Thus, lower thresholds for PA may exist for long term prevention of cardio-metabolic diseases in sedentary overweight subjects.
Collapse
Affiliation(s)
- Karl-Heinz Herzig
- Research Unit of Biomedicine, and Biocenter of Oulu, Oulu University, 90014, Oulu, Finland. .,Department of Gastroenterology and Metabolism, Poznan University of Medical Sciences, Poznan, Poland. .,Medical Research Center and Oulu University Hospital, University of Oulu and Oulu University Hospital, Oulu, Finland.
| | - Juhani Leppäluoto
- Research Unit of Biomedicine, and Biocenter of Oulu, Oulu University, 90014, Oulu, Finland
| | - Jari Jokelainen
- Center for Life Course Health Research, Faculty of Medicine, University of Oulu, 90014, Oulu, Finland.,Oulu University Hospital, Unit of General Practice, and Health Center of Oulu, Oulu, Finland
| | - Emmanuelle Meugnier
- CarMeN Laboratory, INSERM U1060, INRA U1397, University of Lyon, 69600, Oullins, France
| | - Sandra Pesenti
- CarMeN Laboratory, INSERM U1060, INRA U1397, University of Lyon, 69600, Oullins, France
| | - Harri Selänne
- Department of Education and Psychology, University of Jyväskylä, Jyväskylä, Finland
| | - Kari A Mäkelä
- Research Unit of Biomedicine, and Biocenter of Oulu, Oulu University, 90014, Oulu, Finland
| | - Riikka Ahola
- Research Unit of Medical Imaging, Physics and Technology, University of Oulu, 90014, Oulu, Finland
| | - Timo Jämsä
- Medical Research Center and Oulu University Hospital, University of Oulu and Oulu University Hospital, Oulu, Finland.,Research Unit of Medical Imaging, Physics and Technology, University of Oulu, 90014, Oulu, Finland.,Department of Diagnostic Imaging, Oulu University Hospital, Oulu, Finland
| | - Hubert Vidal
- CarMeN Laboratory, INSERM U1060, INRA U1397, University of Lyon, 69600, Oullins, France
| | - Sirkka Keinänen-Kiukaanniemi
- Center for Life Course Health Research, Faculty of Medicine, University of Oulu, 90014, Oulu, Finland.,Oulu University Hospital, Unit of General Practice, and Health Center of Oulu, Oulu, Finland
| |
Collapse
|
21
|
Miller KE, Martz DC, Stoner C, Jowers A, Taheri ML, Sarzynski MA, Davis RA, Plaisance EP. Efficacy of a telephone-based medical nutrition program on blood lipid and lipoprotein metabolism: Results of Our Healthy Heart. Nutr Diet 2017; 75:73-78. [DOI: 10.1111/1747-0080.12366] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 05/03/2017] [Accepted: 05/31/2017] [Indexed: 11/28/2022]
Affiliation(s)
- Kelsey E. Miller
- Department of Human Studies; University of Alabama at Birmingham; Birmingham Alabama USA
| | | | | | | | | | - Mark A. Sarzynski
- Arnold School of Public Health; University of South Carolina; Columbia South Carolina USA
| | - Rachel A.H. Davis
- Department of Human Studies; University of Alabama at Birmingham; Birmingham Alabama USA
| | - Eric P. Plaisance
- Department of Human Studies; Nutrition Obesity Research Center; Center for Exercise Medicine; Comprehensive Diabetes Center; Birmingham Alabama USA
- Department of Nutrition Sciences; Nutrition Obesity Research Center; Center for Exercise Medicine; Comprehensive Diabetes Center; Birmingham Alabama USA
| |
Collapse
|
22
|
Johnson LK, Holven KB, Nordstrand N, Mellembakken JR, Tanbo T, Hjelmesæth J. Fructose content of low calorie diets: effect on cardiometabolic risk factors in obese women with polycystic ovarian syndrome: a randomized controlled trial. Endocr Connect 2015; 4:144-54. [PMID: 26138702 PMCID: PMC4488759 DOI: 10.1530/ec-15-0047] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
We aimed to examine whether a whole-grain crispbread (CB) low-fructose, low-calorie diet (LCD) might be superior to a traditional LCD based on fructose-rich liquid meal replacements (LMRs) with respect to improvement of various cardiometabolic risk factors and reproductive hormones. Parallel-group randomised controlled clinical trial. Morbidly obese women with polycystic ovarian syndrome (PCOS) were randomised to either an 8-week CB-LCD or LMR-LCD (900-1100 kcal/day, fructose 17 g/day or 85 g/day). A total of 51 women completed the study. Body weight, fat mass and waist circumference reduced by mean (s.d.) 10.0 (4.8) kg, 7.4 (4.2) kg and 8.5 (4.4) cm, with no significant differences between groups. Total-cholesterol, HDL-cholesterol and Apo-A1 were significantly reduced within both groups (all P values <0.01), with no significant between-group differences. The triacylglycerol and LDL-cholesterol levels were reduced within the LMR group only, with no significant between-group differences. Blood pressure and most measures of glucose metabolism improved significantly in both diet groups, with no significant between-group difference. Uric acid levels rose by 17.7 (46.4) and 30.6 (71.5) μmol/l in the CB and LMR group, respectively, with no significant difference between groups. Gastrointestinal discomfort was significantly and equally reduced in both intervention groups. Free testosterone index was reduced in both groups, with no significant difference between groups. Morbidly obese women with PCOS who underwent either an 8-week low or high-fructose LCD-diet had similar changes in various cardiometabolic risk factors and reproductive hormones. Registration at ClinicalTrials.gov: NCT00779571.
Collapse
Affiliation(s)
- Line K Johnson
- Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway
| | - Kirsten B Holven
- Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway
| | - Njord Nordstrand
- Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway
| | - Jan R Mellembakken
- Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway
| | - Tom Tanbo
- Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway
| | - Jøran Hjelmesæth
- Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway Morbid Obesity CentreVestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, NorwayDepartment of NutritionInstitute of Basic Medical Sciences, University of Oslo, PO Box 1046 Blindern, 0317 Oslo, NorwayNorwegian National Advisory Unit on Familial HypercholesterolemiaDepartment of Endocrinology, Morbid Obesity and Preventive MedicineDepartment of GynecologyOslo University Hospital, Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, NorwayInstitute of Clinical MedicineDepartment of EndocrinologyMorbid Obesity and Preventive Medicine, Institute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway
| |
Collapse
|
23
|
Wahl S, Vogt S, Stückler F, Krumsiek J, Bartel J, Kacprowski T, Schramm K, Carstensen M, Rathmann W, Roden M, Jourdan C, Kangas AJ, Soininen P, Ala-Korpela M, Nöthlings U, Boeing H, Theis FJ, Meisinger C, Waldenberger M, Suhre K, Homuth G, Gieger C, Kastenmüller G, Illig T, Linseisen J, Peters A, Prokisch H, Herder C, Thorand B, Grallert H. Multi-omic signature of body weight change: results from a population-based cohort study. BMC Med 2015; 13:48. [PMID: 25857605 PMCID: PMC4367822 DOI: 10.1186/s12916-015-0282-y] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/09/2014] [Accepted: 01/20/2015] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND Excess body weight is a major risk factor for cardiometabolic diseases. The complex molecular mechanisms of body weight change-induced metabolic perturbations are not fully understood. Specifically, in-depth molecular characterization of long-term body weight change in the general population is lacking. Here, we pursued a multi-omic approach to comprehensively study metabolic consequences of body weight change during a seven-year follow-up in a large prospective study. METHODS We used data from the population-based Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 cohort. At follow-up (F4), two-platform serum metabolomics and whole blood gene expression measurements were obtained for 1,631 and 689 participants, respectively. Using weighted correlation network analysis, omics data were clustered into modules of closely connected molecules, followed by the formation of a partial correlation network from the modules. Association of the omics modules with previous annual percentage weight change was then determined using linear models. In addition, we performed pathway enrichment analyses, stability analyses, and assessed the relation of the omics modules with clinical traits. RESULTS Four metabolite and two gene expression modules were significantly and stably associated with body weight change (P-values ranging from 1.9 × 10(-4) to 1.2 × 10(-24)). The four metabolite modules covered major branches of metabolism, with VLDL, LDL and large HDL subclasses, triglycerides, branched-chain amino acids and markers of energy metabolism among the main representative molecules. One gene expression module suggests a role of weight change in red blood cell development. The other gene expression module largely overlaps with the lipid-leukocyte (LL) module previously reported to interact with serum metabolites, for which we identify additional co-expressed genes. The omics modules were interrelated and showed cross-sectional associations with clinical traits. Moreover, weight gain and weight loss showed largely opposing associations with the omics modules. CONCLUSIONS Long-term weight change in the general population globally associates with serum metabolite concentrations. An integrated metabolomics and transcriptomics approach improved the understanding of molecular mechanisms underlying the association of weight gain with changes in lipid and amino acid metabolism, insulin sensitivity, mitochondrial function as well as blood cell development and function.
Collapse
|
24
|
Alexandre F, Zago V, Panzoldo N, Parra E, Scherrer D, Vendrame F, Nunes V, Gomes E, Marcato P, Nakandakare E, Quintão E, de Faria E. Reference values for high-density lipoprotein particle size and volume by dynamic light scattering in a Brazilian population sample and their relationships with metabolic parameters. Clin Chim Acta 2015; 442:63-72. [DOI: 10.1016/j.cca.2015.01.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Revised: 01/08/2015] [Accepted: 01/10/2015] [Indexed: 11/17/2022]
|
25
|
Rankin NJ, Preiss D, Welsh P, Burgess KEV, Nelson SM, Lawlor DA, Sattar N. The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. Atherosclerosis 2014; 237:287-300. [PMID: 25299963 PMCID: PMC4232363 DOI: 10.1016/j.atherosclerosis.2014.09.024] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2014] [Revised: 09/01/2014] [Accepted: 09/03/2014] [Indexed: 11/20/2022]
Abstract
The ability to phenotype metabolic profiles in serum has increased substantially in recent years with the advent of metabolomics. Metabolomics is the study of the metabolome, defined as those molecules with an atomic mass less than 1.5 kDa. There are two main metabolomics methods: mass spectrometry (MS) and proton nuclear magnetic resonance (1H NMR) spectroscopy, each with its respective benefits and limitations. MS has greater sensitivity and so can detect many more metabolites. However, its cost (especially when heavy labelled internal standards are required for absolute quantitation) and quality control is sub-optimal for large cohorts. 1H NMR is less sensitive but sample preparation is generally faster and analysis times shorter, resulting in markedly lower analysis costs. 1H NMR is robust, reproducible and can provide absolute quantitation of many metabolites. Of particular relevance to cardio-metabolic disease is the ability of 1H NMR to provide detailed quantitative data on amino acids, fatty acids and other metabolites as well as lipoprotein subparticle concentrations and size. Early epidemiological studies suggest promise, however, this is an emerging field and more data is required before we can determine the clinical utility of these measures to improve disease prediction and treatment. This review describes the theoretical basis of 1H NMR; compares MS and 1H NMR and provides a tabular overview of recent 1H NMR-based research findings in the atherosclerosis field, describing the design and scope of studies conducted to date. 1H NMR metabolomics-CVD related research is emerging, however further large, robustly conducted prospective, genetic and intervention studies are needed to advance research on CVD risk prediction and to identify causal pathways amenable to intervention. 1H NMR metabolomics is being increasingly applied to large cohort studies. Studies have identified potentially novel lipoprotein and metabolite predictors for CVD. Potential exists for the use of metabolomics in cardiovascular clinical practice. Current findings are too preliminary to translate into clinical recommendations. Further large scale studies are now needed to advance the field in a robust manner.
Collapse
Affiliation(s)
- Naomi J Rankin
- BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK; Glasgow Polyomics, Joseph Black Building, University of Glasgow, Glasgow, G12 8QQ, UK.
| | - David Preiss
- BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK
| | - Paul Welsh
- BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK
| | - Karl E V Burgess
- Glasgow Polyomics, Joseph Black Building, University of Glasgow, Glasgow, G12 8QQ, UK
| | - Scott M Nelson
- School of Medicine, University of Glasgow, Glasgow, G12 8TA, UK
| | - Debbie A Lawlor
- MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, BS8 2BN, UK; School of Social and Community Medicine, University of Bristol, Bristol, BS8 2PS, UK
| | - Naveed Sattar
- BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
| |
Collapse
|
26
|
Abstract
Advanced lipid testing has been suggested by some experts to identify patients with substantial residual risk for more aggressive targeting of lifestyle and pharmacologic therapies. It measures the subpopulation of lipoproteins and apolipoproteins, which include lipoprotein (a), apolipoprotein A-I, and apolipoprotein B, and measures of lipoprotein particle composition such as LDL particle (LPL-P) and HDL particle (HDL-P) number and size. Obesity is associated with smaller LDL-P and HDL-P sizes. Moderate weight loss via fasting/calorie restriction is associated with LDL-P size increase, whereas moderate weight loss via endurance exercise is associated with HDL-P size increase. Diets high in carbohydrates are associated with a more atherogenic advanced lipoprotein profile characterized by smaller LDL-P and HDL-P sizes. In summary, lifestyle changes such as weight loss, exercise, and dietary modification correlate with improvement in the profile of advanced lipoproteins. Regrettably, therapies targeting HDL and HDL composition have been disappointing to date.
Collapse
|
27
|
Gene-diet interactions with polymorphisms of the MGLL gene on plasma low-density lipoprotein cholesterol and size following an omega-3 polyunsaturated fatty acid supplementation: a clinical trial. Lipids Health Dis 2014; 13:86. [PMID: 24884512 PMCID: PMC4040477 DOI: 10.1186/1476-511x-13-86] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Accepted: 05/15/2014] [Indexed: 12/12/2022] Open
Abstract
Background Omega-3 (n-3) polyunsaturated fatty acid (PUFA) consumption increases low-density lipoprotein (LDL) cholesterol (C) concentrations and particle size. Studies showed that individuals with large, buoyant LDL particles have decreased risk of cardiovascular diseases. However, a large inter-individual variability is observed in LDL particle size. Genetic factors may explain the variability of LDL-C concentrations and particle size after an n-3 PUFA supplementation. The monoglyceride lipase (MGLL) enzyme, encoded by the MGLL gene, plays an important role in lipid metabolism, especially lipoprotein metabolism. The aim of this study was to investigate if polymorphisms (SNPs) of the MGLL gene influence the variability of LDL-C and LDL particle size in response to an n-3 PUFA supplementation. Methods 210 subjects completed the study. They consumed 5 g/d of a fish oil supplement (1.9-2.2 g eicosapentaenoic acid and 1.1 g docosaexaenoic acid) during 6 weeks. Plasma lipids were measured before and after the supplementation period and 18 SNPs of the MGLL gene, covering 100% of common genetic variations (minor allele frequency ≥0.05), have been genotyped using TaqMan technology (Life Technologies Inc., Burlington, ON, CA). Results Following the n-3 PUFA supplementation, 55% of subjects increased their LDL-C levels. In a model including the supplementation, genotype and supplementation*genotype effects, gene-diet interaction effects on LDL-C concentrations (rs782440, rs6776142, rs555183, rs6780384, rs6787155 and rs1466571) and LDL particle size (rs9877819 and rs13076593) were observed for the MGLL gene SNPs (p < 0.05). Conclusion SNPs within the MGLL gene may modulate plasma LDL-C levels and particle size following an n-3 PUFA supplementation. This trial was registered at clinicaltrials.gov as NCT01343342.
Collapse
|
28
|
Julve J, Pardina E, Pérez-Cuéllar M, Ferrer R, Rossell J, Baena-Fustegueras JA, Fort JM, Lecube A, Blanco-Vaca F, Sánchez-Quesada JL, Peinado-Onsurbe J. Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. Atherosclerosis 2014; 234:200-5. [PMID: 24674904 DOI: 10.1016/j.atherosclerosis.2014.02.034] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2013] [Revised: 02/14/2014] [Accepted: 02/17/2014] [Indexed: 12/13/2022]
Abstract
OBJECTIVE The purpose of this study was to evaluate the effect of weight loss induced in morbidly obese subjects by Roux-en-Y gastric bypass bariatric surgery on the atherogenic features of their plasma lipoproteins. METHODS Twenty-one morbidly obese subjects undergoing bariatric surgery were followed up for up to 1 year after surgery. Plasma and lipoproteins were assayed for chemical composition and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity. Lipoprotein size was assessed by non-denaturing polyacrylamide gradient gel electrophoresis, and oxidised LDL by ELISA. Liver samples were assayed for mRNA abundance of oxidative markers. RESULTS Lipid profile analysis revealed a reduction in the plasma concentrations of cholesterol and triglycerides, which were mainly associated with a significant reduction in the plasma concentration of circulating apoB-containing lipoproteins rather than with changes in their relative chemical composition. All patients displayed a pattern A phenotype of LDL subfractions and a relative increase in the antiatherogenic plasma HDL-2 subfraction (>2-fold; P < 0.001). The switch towards predominantly larger HDL particles was due to an increase in their relative cholesteryl ester content. Excess weight loss also led to a significant decrease in the plasma concentration of oxidised LDL (∼-25%; P < 0.01) and in the total Lp-PLA2 activity. Interestingly, the decrease in plasma Lp-PLA2 was mainly attributed to a decrease in the apoB-containing lipoprotein-bound Lp-PLA2. CONCLUSION Our data indicate that the weight loss induced by bariatric surgery ameliorates the atherogenicity of plasma lipoproteins by reducing the apoB-containing Lp-PLA2 activity and oxidised LDL, as well as increasing the HDL-2 subfraction.
Collapse
Affiliation(s)
- Josep Julve
- Institut d'Investigació Biomèdica de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Eva Pardina
- Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
| | - Montserrat Pérez-Cuéllar
- Institut d'Investigació Biomèdica de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain
| | - Roser Ferrer
- Departament de Bioquímica i Unitat de Cirurgia, Institut de Recerca Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Joana Rossell
- Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
| | | | - José Manuel Fort
- Departament de Bioquímica i Unitat de Cirurgia, Institut de Recerca Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Albert Lecube
- Departament d'Endocrinologia i Nutrició, Hospital Universitari Arnau de Vilanova, Universitat de Lleida, Lleida, Spain; Unitat de Recerca en Diabetes i Metabolisme, Institut de Recerca Hospital Universitari Vall d'Hebron, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Francisco Blanco-Vaca
- Institut d'Investigació Biomèdica de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas, CIBERDEM, Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - José Luis Sánchez-Quesada
- Institut d'Investigació Biomèdica de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain
| | - Julia Peinado-Onsurbe
- Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
| |
Collapse
|
29
|
Miksztowicz V, Schreier L, McCoy M, Lucero D, Fassio E, Billheimer J, Rader DJ, Berg G. Role of SN1 lipases on plasma lipids in metabolic syndrome and obesity. Arterioscler Thromb Vasc Biol 2014; 34:669-75. [PMID: 24458708 DOI: 10.1161/atvbaha.113.303027] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To assess the phospholipase activity of endothelial (EL) and hepatic lipase (HL) in postheparin plasma of subjects with metabolic syndrome (MS)/obesity and their relationship with atherogenic and antiatherogenic lipoproteins. Additionally, to evaluate lipoprotein lipase (LPL) and HL activity as triglyceride (TG)-hydrolyses to complete the analyses of SN1 lipolytic enzymes in the same patient. APPROACH AND RESULTS Plasma EL, HL, and LPL activities were evaluated in 59 patients with MS and 36 controls. A trend toward higher EL activity was observed in MS. EL activity was increased in obese compared with normal weight group (P=0.009) and was negatively associated with high-density lipoprotein-cholesterol (P=0.014 and P=0.005) and apolipoprotein A-I (P=0.045 and P=0.001) in control and MS group, respectively. HL activity, as TG-hydrolase, was increased in MS (P=0.025) as well as in obese group (P=0.017); directly correlated with low-density lipoprotein-cholesterol (P=0.005) and apolipoprotein B (P=0.003) and negatively with high-density lipoprotein-cholesterol (P=0.021) in control group. LPL was decreased in MS (P<0.001) as well as in overweight and obese compared with normal weight group (P=0.015 and P=0.004, respectively); inversely correlated %TG-very low-density lipoproteins (P=0.04) and TG/apolipoprotein B index (P=0.013) in control group. These associations were not found in MS. CONCLUSIONS We describe for the first time EL and HL activity as phospholipases in MS/obesity, being both responsible for high-density lipoprotein catabolism. Our results elucidate part of the remaining controversies about SN1 lipases activity in MS and different grades of obesity. The impact of insulin resistance on the activity of the 3 enzymes determines the lipoprotein alterations observed in these states.
Collapse
Affiliation(s)
- Verónica Miksztowicz
- From the Laboratory of Lipids and Lipoproteins, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry, Institute of Physiopathology and Clinical Biochemistry, University of Buenos Aires, Argentina (V.M., L.S., D.L., G.B.); Institute for Translational Medicine and Therapeutics, School of Medicine, University of Pennsylvania, PA (M.M., J.B., D.J.R.); and Department of Gastroenterology, National Hospital Prof. A. Posadas, Buenos Aires, Argentina (E.F.)
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Frestedt JL, Young LR, Bell M. Meal Replacement Beverage Twice a Day in Overweight and Obese Adults (MDRC2012-001). CURRENT NUTRITION & FOOD SCIENCE 2012; 8:320-329. [PMID: 23236298 PMCID: PMC3514724 DOI: 10.2174/157340112803832156] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2012] [Revised: 09/23/2012] [Accepted: 10/10/2012] [Indexed: 12/27/2022]
Abstract
This open label, single arm, prospective, interventional, weight loss trial evaluated a meal replacement beverage
(Right Size® Smoothie) used to replace breakfast and lunch each day for 12 weeks (7 clinic visits) as part of a calorie-restricted
diet in overweight and obese adults. A total of 155 individuals were screened, 55 enrolled and 28 completed this
12 week study. Subjects were obese (mean weight: 206 pounds and BMI: 32.7 kg/m2) and the mean age was 40 years including
42 (76.4%) female and 13 (23.6%) male volunteers. The modified Intent to Treat and Completer groups lost an
average of 10.6 and 13.8 pounds and reduced their average BMI by 1.7 and 2.2 kg/m2 respectively during this 12 week
trial. The Per Protocol group lost 15.2 pounds and 2.4 kg/m2 and the Optimal Weight Loss group lost 18.5 pounds and 2.9
kg/m2. Using the Satiety Labeled Intensity Magnitude scale (SLIM) questionnaire, subjects reported feeling relatively
hungry before they consumed the beverage, then feeling relatively full 15 minutes following the beverage with the sensation
of some fullness lasting more than 2 hours and then feeling relatively hungry again at 3 hours after consuming the
beverage. Study subjects reported significant improvements in physical functioning, general health, vitality and mental
health as well as increased cognitive restraint of eating, reduced disinhibition and reduced hunger during the trial. The
study beverages were well tolerated and no Serious Adverse Events (SAE) reported. This study suggests the study beverage
aids in weight loss by helping to curb hunger during a reduced calorie diet program.
Collapse
Affiliation(s)
- Joy L Frestedt
- Alimentex , Minnesota Diet Research Center, Frestedt Incorporated, St Louis Park, MN
| | | | | |
Collapse
|